{rfName}
Er

Indexed in

License and use

Citations

16

Altmetrics

Analysis of institutional authors

Carcereny, EAuthorRosell, RAuthor

Share

April 6, 2015
Publications
>
Article
No

Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial

Publicated to:Future Oncology. 11 (3): 421-429 - 2015-02-01 11(3), DOI: 10.2217/fon.14.269

Authors: de Marinis, F; Vergnenegre, A; Passaro, A; Dubos-Arvis, C; Carcereny, E; Drozdowskyj, A; Zeaiter, A; Perez-Moreno, P; Rosell, R

Affiliations

CHU Limoges, Hop Cluzeau, Limoges, France - Author
Ctr Francois Baclesse, F-14021 Caen, France - Author
European Inst Oncol, Div Thorac Oncol, Milan, Italy - Author
F Hoffmann La Roche, Basel, Switzerland - Author
High Specializat Hosp, Rome, Italy - Author
Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain - Author
PIVOTAL SL, Madrid, Spain - Author
See more

Abstract

This analysis investigates incidence and time course of rash in the EURTAC study.Patients with EGFR mutation-positive non-small-cell lung cancer were randomized 1:1 to receive once daily erlotinib or 3-weekly cycles of chemotherapy.Of the 86 erlotinib-treated patients, 71 reported rash. Median time to first rash appearance was 0.7 months. Most patients (n = 65) had the same or lower grade rash at final assessment compared with initial assessment. Of the 21 patients with decreased rash grade between initial and final assessments, 61.9% received no erlotinib dose modification, 42.8% had no concomitant rash treatment.Most rash cases were mild, occurred within 1 month of erlotinib treatment, and rapidly improved without the need for erlotinib dose alterations.

Keywords

1st-line treatmentcarboplatinchemotherapyctong-0802cutaneous toxicitiesegfrerlotinibmulticenternon-small-cell lung canceropen-labelphase-iiirashsafetyskin toxicitiesEgfrErlotinibNon-small-cell lung cancerQuality-of-lifeRashSafety

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Future Oncology due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2015, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Medicine (Miscellaneous).

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 1.31, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-10, the following number of citations:

  • WoS: 8
  • Scopus: 8

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-10:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 31 (PlumX).

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: France; Italy; London; Switzerland.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (Rosell Costa, Rafael).